William Blair Reiterates Outperform Rating for Arcturus Therapeutics (NASDAQ:ARCT)

Arcturus Therapeutics (NASDAQ:ARCT)‘s stock had its “outperform” rating reissued by equities research analysts at William Blair in a report issued on Thursday, RTT News reports.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Arcturus Therapeutics in a research report on Wednesday, March 20th. Canaccord Genuity Group cut their price target on Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating on the stock in a report on Friday, May 10th. Finally, Citigroup raised their target price on shares of Arcturus Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research report on Thursday, February 8th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $64.86.

Arcturus Therapeutics Stock Performance

NASDAQ:ARCT opened at $30.41 on Thursday. The company has a market capitalization of $818.94 million, a P/E ratio of -7.78 and a beta of 2.65. The stock’s 50 day moving average price is $30.09 and its 200 day moving average price is $30.83. Arcturus Therapeutics has a 52 week low of $17.52 and a 52 week high of $43.81.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.69) by $1.37. Arcturus Therapeutics had a negative net margin of 81.59% and a negative return on equity of 37.61%. The business had revenue of $33.99 million for the quarter, compared to analyst estimates of $64.14 million. As a group, sell-side analysts forecast that Arcturus Therapeutics will post -4.39 earnings per share for the current fiscal year.

Insider Transactions at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 17,435 shares of the company’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $35.02, for a total value of $610,573.70. Following the sale, the chief operating officer now owns 473,448 shares in the company, valued at approximately $16,580,148.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 13.80% of the stock is owned by insiders.

Institutional Trading of Arcturus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ARCT. Commonwealth Equity Services LLC raised its holdings in Arcturus Therapeutics by 27.7% during the 3rd quarter. Commonwealth Equity Services LLC now owns 14,739 shares of the biotechnology company’s stock valued at $377,000 after buying an additional 3,200 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Arcturus Therapeutics by 3.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 94,427 shares of the biotechnology company’s stock worth $2,413,000 after buying an additional 3,587 shares in the last quarter. MGO One Seven LLC lifted its position in shares of Arcturus Therapeutics by 4.4% in the third quarter. MGO One Seven LLC now owns 23,688 shares of the biotechnology company’s stock worth $605,000 after buying an additional 1,000 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in Arcturus Therapeutics by 5.9% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,853 shares of the biotechnology company’s stock worth $277,000 after purchasing an additional 606 shares during the period. Finally, Barclays PLC grew its holdings in shares of Arcturus Therapeutics by 15.5% in the third quarter. Barclays PLC now owns 112,467 shares of the biotechnology company’s stock worth $2,873,000 after purchasing an additional 15,112 shares during the last quarter. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.